A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment

• Main Authors: Jiangtao Fu (Author), Pingping Zhang (Author), Zhiguo Sun (Author), Guodong Lu (Author), Qi Cao (Author), Yiting Chen (Author), Wenbin Wu (Author), Jiabao Zhang (Author), Chunlin Zhuang (Author), Chunquan Sheng (Author), Jiajun Xu (Author), Ying Lu (Author), Pei Wang (Author)
• Format: Book
• Published: Elsevier, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist with favorable effects on fatty and glucose metabolism, has been considered the leading candidate drug for nonalcoholic steatohepatitis (NASH) treatment. However, its limited effectiveness in resolving liver fibrosis and lipotoxicity-induc...